Demands are increasing in Congress and around the world that drug companies set affordable prices on coronavirus treatments and vaccines and distribute them equitably. Specialists in drug development called Ridgeback’s turnaround unusually rapid. Start-ups looking to profit by securing rights to new molecules and nurturing their early-stage development are an ingrained part of the ecosystem of drug development. With the coronavirus creating huge demand, that activity is accelerating, say specialists in drug licensing and intellectual property. It started its safety trial on April 10, testing the EIDD-2801 drug against a placebo in 122 healthy volunteers in England, according to its disclosure on clinicaltrials.gov.

Source: Washington Post June 11, 2020 23:15 UTC